The FDA granted a supplemental approval for Casgevy (exagamglogene autotemcel) in patients as young as 2 years old with sickle cell disease or transfusion-dependent beta thalassemia. The therapy was previously approved only for patients 12 and older.
Healthcare & FDA
FDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market
Expanding the approved age to 2-year-olds more than doubles the addressable patient pool for the world's first CRISPR gene therapy.
1-YEAR MOVE
VRTX
▲22.1%
| Ticker | Company | 1-year change |
|---|---|---|
| VRTX | Vertex Pharmaceuticals | +22.1% |
Every 2-year-old who gets Casgevy is a patient bluebird bio and Pfizer's chronic-therapy franchise can never get back.
Who cashes in: Casgevy is co-owned by Vertex Pharmaceuticals VRTX and CRISPR Therapeutics CRSP. Vertex handles commercialization and books the revenue; CRISPR receives royalties. Lowering the age threshold to 2 opens the pediatric SCD population — a group with high disease burden and parents who are highly motivated to pursue a one-time curative option over a lifetime of transfusions. For VRTX, this is incremental revenue on an already-approved asset with no additional clinical trial cost. For CRSP, it's a royalty stream expansion with zero incremental spend. Neither stock is a pure-play on Casgevy alone — VRTX has a massive cystic fibrosis franchise — but the label expansion is a clean positive.
Who's exposed: bluebird bio (BLUE) markets Lyfgenia, a competing gene therapy for SCD, approved for patients 12 and older. Casgevy's pediatric expansion widens the competitive gap: bluebird has no comparable pediatric data filed, and its financial position is fragile. Every patient who chooses Casgevy at age 2 is a patient bluebird can never recapture. Global Blood Therapeutics (now part of Pfizer, PFE) sells Oxbryta, a chronic oral SCD therapy — a curative gene therapy pulling patients permanently off maintenance drugs is a structural headwind for that franchise.
Watch whether Vertex's commercial team can actually place Casgevy in pediatric treatment centers, which require specialized infrastructure. Uptake velocity in the under-12 cohort over the next two quarters is the real tell on whether the label expansion translates to revenue or just optionality.
Source: original report ↗
Free alerts
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.